OR WAIT 15 SECS
Zealand will join efforts with Eli Lilly to design and develop therapeutic peptides for Type 2 diabetes and obesity.
Zealand Pharma, a biopharmaceutical company based in Copenhagen specializing in peptides, has formed a peptide drug R+D collaboration agreement with Eli Lilly.
Under the agreement, Zealand will collaborate with Eli Lilly in the design and development of peptide therapeutics for the treatment of Type 2 diabetes and obesity. The companies will share in the funding, risk, and reward of the program. Future expansion of the collaboration to additional drug targets and disease areas is possible. No financial terms of the agreement have been disclosed.
Source: Zealand Pharma